Ozempic and Wegovy prescriptions increase this quarter?
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
%
forecast
▼
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
6H
1D
1W
1M
ALL
Q1 2025
% Chance
$197,977vol
5% or above
90%
-1
5% or above
90%
-1
7% or above
69%
7% or above
69%
10% or above
11%
-8
10% or above
11%
-8
2 more markets
Rules summary for
7% or above
If prescriptions made for weight loss drugs (using semaglutide and tirzepatide) grow by 7% in Q1 2025, then the market resolves to Yes. Outcome verified from IQVIA.
The number of weight drug prescriptions at the end of Q1 2025 has not been sent to the Kalshi team yet.
Timeline and payout
About
Ozempic and Wegovy are poised for record-breaking sales in 2023 and going into 2024, as demand for these medications skyrockets. Will the surge in prescriptions continue, or will the market eventually reach saturation point?